Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Alfredo Sanchez-Hernandez"'
Autor:
Cristina Candal-Pedreira, Alberto Ruano-Ravina, Virginia Calvo de Juan, Manuel Cobo, José Manuel Trigo, Enric Carcereny, Marc Cucurull, Rafael López Castro, Eduardo Solís García, Amparo Sánchez-Gastaldo, Bartomeu Massutí, Delvys Rodríguez-Abreu, Anna Estival, María Guirado Risueño, María Pamiés Ramón, Rosario García Campelo, Guillermo Alonso-Jáudenes, Carlos Camps, Edel del Barco Morillo, Clara González Ojea, Manuel Dómine, Alfredo Sanchez-Hernandez, Joaquím Bosch-Barrera, María Ángeles Sala González, Mariano Provencio
Publikováno v:
ERJ Open Research, Vol 9, Iss 6 (2023)
Objectives The aim of the study was to ascertain the percentage of Spanish lung cancer cases that would fulfil the lung cancer screening inclusion criteria recommended by the United States Preventive Service Task Force (USPSTF) in 2013 and 2021. Meth
Externí odkaz:
https://doaj.org/article/a612acb88ba047f79e4cc339b0b86a9c
Autor:
Ana Delgado-Prada, Julián Borrás, Roxana Farzanegan, María Cruz Torres Gorriz, Adrián Germán-Sánchez, Raquel Cervera Aznar, Isabela Raducan, Jose Vicente Castelló, Alfredo Sanchez-Hernandez, Ernesto Enrique
Publikováno v:
Clinical and Molecular Allergy, Vol 20, Iss 1, Pp 1-4 (2022)
Abstract Background Ifosfamide is an alkylating agent used in the treatment of a wide range of tumours. Because of known side effects it is usually administered in combination with mesna, a thiol agent with uroprotective activity, to reduce them and
Externí odkaz:
https://doaj.org/article/f089568cbcee4426b45074593ab110cf
Autor:
Renata Ferrarotto, Ian Anderson, Balazs Medgyasszay, Maria Rosario García‐Campelo, William Edenfield, Trevor M. Feinstein, Jennifer M. Johnson, Sujith Kalmadi, Philip E. Lammers, Alfredo Sanchez‐Hernandez, Yili Pritchett, Shannon R. Morris, Rajesh K. Malik, Tibor Csőszi
Publikováno v:
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Abstract Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transf
Externí odkaz:
https://doaj.org/article/67201ebc01a245ac809c92ab296cf9ee
Autor:
Julián Borrás Cuartero, Roxana Farzanegan Miñano, María Cruz Torres Gorriz, Adrián Germán Sánchez, Raquel Cervera Aznar, Isabela Raducan, Jose Vicente Castelló Carrascosa, Alfredo Sanchez Hernandez, Ernesto Enrique
Publikováno v:
Frontiers in Allergy, Vol 3 (2022)
One of the main objectives when assessing patients who react to antineoplastics must be to ensure that they receive the required treatments without delay. From January to July 2021, at the Allergy Department at the Provincial University Consortium Ho
Externí odkaz:
https://doaj.org/article/71bbe81f5ddd4c53a74e01940e29b3ab
Autor:
David Olmos, Miguel Rodrigo, Carlos Di Capua, Guillermo Velasco, Carlos Ferrer, David Lorente, Rebeca Lozano, Ángel Sánchez-Iglesias, Elena Castro, Nuria Romero-Laorden, Casilda Llácer, Alfredo Sanchez-Hernandez
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
Instituto de Salud Carlos III (ISCIII)
Most available prognostic nomograms in metastatic castration-resistant prostate cancer (mCRPC) are derived from datasets not representative of the current treatment landscape. A prognostic nomogram for first-line mCRPC treatment was developed from pa
Autor:
Rajesh K. Malik, Yili Pritchett, Jennifer Johnson, Balazs Medgyasszay, Shannon R. Morris, Renata Ferrarotto, Trevor M. Feinstein, William Jeffery Edenfield, Maria Rosario García-Campelo, Ian Anderson, Tibor Csőszi, Alfredo Sanchez-Hernandez, Sujith Kalmadi, Philip E. Lammers
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transfusions, a
Autor:
Ana Delgado-Prada, Julián Borrás Cuartero, Roxana Farzanegan Miñano, Maria Cruz Torres Gorriz, Adrián Germán-Sánchez, Raquel Cervera Aznar, Isabela Raducan, Jose Vicente Castelló Carrascosa, Alfredo Sanchez-Hernandez, Ernesto Enrique Miranda
BackgroundIfosfamide is an antineoplastic agent with alkylating activity usually administered in combination with mesna. The latter is a thiol agent with uroprotective activity that prevents side effects such as haemorrhagic cystitis or nephrotoxicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7379d9f03f207cf73785b44e838e3c64
https://doi.org/10.21203/rs.3.rs-1296892/v1
https://doi.org/10.21203/rs.3.rs-1296892/v1
Autor:
Roy S. Herbst, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Chu, Isabelle Monnet, Alfredo Sanchez-Hernandez, Shaker Dakhil, D. Ross Camidge, Leanne Winzer, Yee Soo-Hoo, Zachary A. Cooper, Rakesh Kumar, John Bothos, Charu Aggarwal, Alex Martinez-Marti
Publikováno v:
Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Scientia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Scientia
PURPOSE Durvalumab significantly improves overall survival for patients with unresectable stage III non–small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0642b904bde8dff801a491fde48a500f
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6931
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6931
Autor:
Nuria Piera, Marta Benet, Lourdes Cordón, José García-Sánchez, Javier Garde-Noguera, M. A. de la Casa de Julian, L. Gonzalez-Castillo, Alfredo Sanchez-Hernandez, Agustín Lahoz, Julian Carretero, M.C. Gomez-Soler, V. Ruiz, David Lorente, Marta Piqueras, O. Juan-Vidal
Publikováno v:
Journal of Thoracic Oncology. 16:S788-S789
Autor:
E. García-Veros, Roberto Serna-Blasco, Alberto Cruz-Bermúdez, V. Calvo, M. Casarrubios, M. Provencio, Belén Sierra-Rodero, A. Romero, Alfredo Sanchez-Hernandez, Estela Sánchez-Herrero, Raquel Laza-Briviesca, A. Rodriguez-Festa, X. Mielgo-Rubio, E.A. Uribelarrea, Sandra Sanz-Moreno
Publikováno v:
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
ESMO Open
instname
ESMO Open
Background: KRAS is mutated in ∼30% of non-small-cell lung cancer (NSCLC) but it has also been identified as one of the mechanisms underlying resistance to tyrosine kinase inhibitors (TKIs) in EGFR-positive NSCLC patients. Novel KRAS inhibitors tar